GSK's Blenrep Shows 42% Survival Benefit in DREAMM-7 Myeloma Study, Eyes Market Reentry Against J&J's Darzalex
GSK is actively strategizing a market reentry for Blenrep based on promising data from the Phase III DREAMM-7 study. The study highlights that, when Blenrep is used in combination with bortezomib and dexamethasone, it significantly reduces the death risk by 42% compared to Johnson & Johnson's Darzalex in patients with relapsed or refractory multiple myeloma[1][2]. With an estimated median overall survival of 84 months for Blenrep users versus 51 months for those on Darzalex, GSK is reinforcing Blenrep's potential to significantly impact treatment protocols[1]. Additionally, GSK is addressing previous challenges such as ocular toxicities by modifying dosing practices, as they aim for broader approval and market success[2].
References
Explore Further
What strategies is GSK implementing to mitigate the ocular toxicity of Blenrep?
How does the DREAMM-7 study compare with previous studies that assessed Blenrep's efficacy?
What are the potential market implications if the FDA approves Blenrep for second-line treatment?
How does Blenrep's combination with bortezomib and dexamethasone enhance its effectiveness compared to Darzalex alone?
What role do AI-driven collaborations play in GSK's ongoing research and development efforts for Blenrep?